Identification

Name
Aceprometazine
Accession Number
DB01615
Type
Small Molecule
Groups
Approved
Description

Aceprometazine (INN) is a prescription drug with neuroleptic and anti-histamine properties. It is not widely prescribed. It may be used in combination with meprobamate for the treatment of sleep disorders. This combination is available in France under the trade name Mepronizine. [Wikipedia]

Structure
Thumb
Synonyms
  • 10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone
  • Aceprometazina
  • Aceprometazinum
  • Acepromethazine
International/Other Brands
Mepronizine
Categories
UNII
984N9YTM4Y
CAS number
13461-01-3
Weight
Average: 326.456
Monoisotopic: 326.145284026
Chemical Formula
C19H22N2OS
InChI Key
XLOQNFNTQIRSOX-UHFFFAOYSA-N
InChI
InChI=1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3
IUPAC Name
1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethan-1-one
SMILES
CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O)N(C)C

Pharmacology

Indication

Aceprometazine is often used in combination with meprobamate for the treatment of sleep disorders.

Pharmacodynamics

Aceprometazine is a drug with neuroleptic and anti-histamine properties. It is not widely prescribed.

Mechanism of action

Aceprometazine, acting as an H1-receptor antagonist can induce sedation by being able to cross the blood-brain-barrier and binding to H1-receptors in the central nervous system.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineAceprometazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAceprometazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineAceprometazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAceprometazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Aceprometazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Aceprometazine is combined with 7-Nitroindazole.Experimental
AcebutololAceprometazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Aceprometazine.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Aceprometazine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Allopregnanolone.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aceprometazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Aceprometazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Aceprometazine.Approved, Illicit, Investigational
AlprenololAceprometazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Amiodarone.Approved, Investigational
AmisulprideAceprometazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Aceprometazine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Aceprometazine.Approved, Illicit
AmodiaquineThe serum concentration of Aceprometazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amperozide.Experimental
AmphetamineAceprometazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Aceprometazine.Approved, Investigational
ArotinololAceprometazine may increase the hypotensive activities of Arotinolol.Investigational
ArtemetherThe serum concentration of Aceprometazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Aceprometazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Aceprometazine can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of Aceprometazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Aceprometazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Aceprometazine.Approved
AtenololAceprometazine may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of Aceprometazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Azaperone.Investigational, Vet Approved
AzelastineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Aceprometazine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Aceprometazine.Illicit
BefunololAceprometazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Aceprometazine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Aceprometazine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineAceprometazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Aceprometazine.Approved, Investigational
BetaxololAceprometazine may increase the hypotensive activities of Betaxolol.Approved, Investigational
BevantololAceprometazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideAceprometazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololAceprometazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololAceprometazine may increase the hypotensive activities of Bopindolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Aceprometazine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Aceprometazine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aceprometazine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Aceprometazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololAceprometazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolAceprometazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Aceprometazine.Approved, Investigational
BupranololAceprometazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Aceprometazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aceprometazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Aceprometazine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Aceprometazine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aceprometazine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aceprometazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Aceprometazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Aceprometazine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Aceprometazine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Aceprometazine.Approved
CarteololAceprometazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Aceprometazine.Approved, Investigational
CeliprololAceprometazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Aceprometazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Aceprometazine.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aceprometazine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Aceprometazine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Aceprometazine.Approved
ChloroquineThe serum concentration of Aceprometazine can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Chlorphenamine.Approved
ChlorphentermineAceprometazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Aceprometazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aceprometazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Aceprometazine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Aceprometazine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Aceprometazine.Approved, Vet Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Aceprometazine.Approved, Investigational
CitalopramThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Citalopram.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Aceprometazine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Aceprometazine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Aceprometazine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Aceprometazine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Aceprometazine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clopenthixol.Experimental
CloranololAceprometazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aceprometazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Aceprometazine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Aceprometazine.Approved, Illicit
CodeineThe risk or severity of hypotension and central nervous system depression can be increased when Aceprometazine is combined with Codeine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Aceprometazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aceprometazine.Approved
Cycloguanil embonateThe serum concentration of Aceprometazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Aceprometazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Aceprometazine.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aceprometazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Aceprometazine can be increased when it is combined with Dapsone.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Aceprometazine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Aceprometazine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Aceprometazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Aceprometazine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aceprometazine.Approved, Vet Approved
DextroamphetamineAceprometazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Aceprometazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Aceprometazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Aceprometazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Aceprometazine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Aceprometazine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Aceprometazine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Aceprometazine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Aceprometazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Aceprometazine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Aceprometazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Aceprometazine.Experimental, Illicit
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Aceprometazine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aceprometazine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Doramectin.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dotarizine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Aceprometazine.Approved, Investigational
DoxycyclineThe serum concentration of Aceprometazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Aceprometazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Aceprometazine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Aceprometazine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Aceprometazine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Aceprometazine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Aceprometazine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Aceprometazine.Approved, Investigational
EpanololAceprometazine may increase the hypotensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Eperisone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aceprometazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aceprometazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aceprometazine.Approved
EsatenololAceprometazine may increase the hypotensive activities of Esatenolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Escitalopram.Approved, Investigational
EsmololAceprometazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Aceprometazine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aceprometazine.Approved, Investigational
EthanolAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aceprometazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Aceprometazine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Aceprometazine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Aceprometazine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Aceprometazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Aceprometazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Aceprometazine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Aceprometazine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Aceprometazine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Aceprometazine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Aceprometazine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of hypotension and central nervous system depression can be increased when Aceprometazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Aceprometazine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Aceprometazine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Aceprometazine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Aceprometazine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Aceprometazine.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Aceprometazine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Aceprometazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aceprometazine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Aceprometazine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Aceprometazine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Aceprometazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aceprometazine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Aceprometazine.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Aceprometazine.Approved, Illicit, Investigational
GepefrineAceprometazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Aceprometazine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Aceprometazine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Aceprometazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Aceprometazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Aceprometazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Aceprometazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Aceprometazine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Aceprometazine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aceprometazine.Approved, Investigational
HydrocodoneAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aceprometazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetamineAceprometazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Aceprometazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aceprometazine.Approved, Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Aceprometazine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Aceprometazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Indalpine.Investigational, Withdrawn
IndenololAceprometazine may increase the hypotensive activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Indiplon.Investigational
Iofetamine I-123Aceprometazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe therapeutic efficacy of Aceprometazine can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Aceprometazine.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Aceprometazine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aceprometazine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Aceprometazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ketobemidone.Approved, Investigational
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Aceprometazine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Aceprometazine.Approved, Investigational
LandiololAceprometazine may increase the hypotensive activities of Landiolol.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Aceprometazine.Approved, Investigational
LevobetaxololAceprometazine may increase the hypotensive activities of Levobetaxolol.Approved, Investigational
LevobunololAceprometazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Aceprometazine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Aceprometazine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Aceprometazine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Aceprometazine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aceprometazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Aceprometazine.Approved, Investigational
LisdexamfetamineAceprometazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Aceprometazine.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Aceprometazine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aceprometazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Aceprometazine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Aceprometazine.Approved
LumefantrineThe serum concentration of Aceprometazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Aceprometazine.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Magnesium citrate.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe therapeutic efficacy of Aceprometazine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Aceprometazine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Aceprometazine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Aceprometazine can be increased when it is combined with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Aceprometazine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Melperone.Approved, Investigational
MephedroneAceprometazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAceprometazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololAceprometazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aceprometazine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aceprometazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Aceprometazine.Approved, Vet Approved
MequitazineAceprometazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aceprometazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Aceprometazine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Aceprometazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Aceprometazine.Approved, Illicit
MethamphetamineAceprometazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Aceprometazine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Aceprometazine.Approved
MethotrimeprazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aceprometazine.Approved, Investigational, Vet Approved
MethoxyphenamineAceprometazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Aceprometazine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Aceprometazine.Approved
MetipranololAceprometazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aceprometazine.Approved, Investigational
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Aceprometazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Aceprometazine.Approved, Investigational
MetyrosineAceprometazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Aceprometazine.Approved, Illicit
MidomafetamineAceprometazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Investigational
MirtazapineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Aceprometazine can be increased when it is combined with Mizoribine.Investigational
MMDAAceprometazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Aceprometazine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Aceprometazine.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Aceprometazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved, Investigational
NadololAceprometazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aceprometazine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Aceprometazine.Approved, Investigational
NebivololAceprometazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Nefazodone.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Neomycin.Approved, Vet Approved
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Aceprometazine.Approved, Investigational
NicomorphineAceprometazine may increase the hypotensive activities of Nicomorphine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Aceprometazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Aceprometazine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Aceprometazine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Aceprometazine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aceprometazine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Aceprometazine.Approved
OpiumThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Opium.Approved, Illicit
OrphenadrineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aceprometazine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Aceprometazine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Aceprometazine.Approved, Investigational
OxycodoneThe risk or severity of hypotension and central nervous system depression can be increased when Aceprometazine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of hypotension and central nervous system depression can be increased when Aceprometazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Aceprometazine.Approved
ParaldehydeAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Paroxetine.Approved, Investigational
PenbutololAceprometazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aceprometazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Aceprometazine.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Aceprometazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aceprometazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aceprometazine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Phenibut.Experimental
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Aceprometazine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Aceprometazine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Phenoxyethanol.Approved
PhentermineAceprometazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Aceprometazine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Aceprometazine.Approved
PindololAceprometazine may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pipamperone.Approved, Investigational
PiperaquineThe serum concentration of Aceprometazine can be increased when it is combined with Piperaquine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Aceprometazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Aceprometazine.Approved
Platelet Activating FactorAceprometazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Aceprometazine.Approved
PractololAceprometazine may increase the hypotensive activities of Practolol.Approved
PramipexoleAceprometazine may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Aceprometazine.Approved, Illicit
PregabalinThe therapeutic efficacy of Aceprometazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Aceprometazine.Approved
PrimaquineThe serum concentration of Aceprometazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Aceprometazine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Aceprometazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aceprometazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aceprometazine.Approved, Vet Approved
ProguanilThe serum concentration of Aceprometazine can be increased when it is combined with Proguanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Aceprometazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Aceprometazine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Aceprometazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Aceprometazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Aceprometazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Aceprometazine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Aceprometazine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Aceprometazine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Aceprometazine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pyrantel.Approved, Vet Approved
PyrimethamineThe serum concentration of Aceprometazine can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of Aceprometazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Aceprometazine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Aceprometazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Aceprometazine.Approved, Investigational
QuinidineThe serum concentration of Aceprometazine can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Aceprometazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Aceprometazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Aceprometazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aceprometazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aceprometazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aceprometazine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Aceprometazine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Aceprometazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ritanserin.Investigational
RitobegronAceprometazine may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Aceprometazine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Romifidine.Vet Approved
RopiniroleAceprometazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Aceprometazine.Approved
RotigotineAceprometazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Aceprometazine.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Aceprometazine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Aceprometazine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aceprometazine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aceprometazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Aceprometazine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aceprometazine.Approved, Vet Approved
SinefunginThe serum concentration of Aceprometazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
SotalolAceprometazine may increase the hypotensive activities of Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Aceprometazine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aceprometazine.Approved, Investigational
SulfadoxineThe serum concentration of Aceprometazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Aceprometazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideAceprometazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Aceprometazine.Approved, Investigational
SuvorexantAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TafenoquineThe serum concentration of Aceprometazine can be increased when it is combined with Tafenoquine.Approved, Investigational
TalinololAceprometazine may increase the hypotensive activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Aceprometazine.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aceprometazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Aceprometazine.Approved, Investigational
TerbutalineAceprometazine may increase the hypotensive activities of Terbutaline.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Terodiline.Experimental
TertatololAceprometazine may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aceprometazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of QTc prolongation can be increased when Tetrandrine is combined with Aceprometazine.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetrodotoxin.Investigational
ThalidomideAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aceprometazine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Aceprometazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Aceprometazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Aceprometazine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tilidine.Experimental
TimololAceprometazine may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Aceprometazine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Aceprometazine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Aceprometazine.Approved
TramadolThe risk or severity of hypotension and central nervous system depression can be increased when Aceprometazine is combined with Tramadol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aceprometazine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Aceprometazine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Aceprometazine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aceprometazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aceprometazine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Aceprometazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Aceprometazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Aceprometazine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Valproic AcidThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Valproic Acid.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aceprometazine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Aceprometazine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Aceprometazine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aceprometazine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Aceprometazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Aceprometazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aceprometazine.Approved, Investigational
ZolpidemAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Aceprometazine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Aceprometazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Aceprometazine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015553
PubChem Compound
26035
PubChem Substance
46506646
ChemSpider
24249
ChEBI
53770
ChEMBL
CHEMBL2104054
Therapeutic Targets Database
DAP001075
PharmGKB
PA164743727
Wikipedia
Aceprometazine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP4.35ALOGPS
logP3.85ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)16.06ChemAxon
pKa (Strongest Basic)8.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity98.91 m3·mol-1ChemAxon
Polarizability36.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9852
Caco-2 permeable+0.8427
P-glycoprotein substrateSubstrate0.8358
P-glycoprotein inhibitor IInhibitor0.9139
P-glycoprotein inhibitor IIInhibitor0.5926
Renal organic cation transporterInhibitor0.5135
CYP450 2C9 substrateNon-substrate0.7768
CYP450 2D6 substrateSubstrate0.8188
CYP450 3A4 substrateSubstrate0.5876
CYP450 1A2 substrateInhibitor0.8793
CYP450 2C9 inhibitorNon-inhibitor0.9009
CYP450 2D6 inhibitorInhibitor0.7954
CYP450 2C19 inhibitorNon-inhibitor0.8674
CYP450 3A4 inhibitorNon-inhibitor0.7954
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5333
Ames testNon AMES toxic0.8613
CarcinogenicityNon-carcinogens0.8886
BiodegradationNot ready biodegradable0.9941
Rat acute toxicity2.6833 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9729
hERG inhibition (predictor II)Inhibitor0.7319
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Acetophenones / Aryl alkyl ketones / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Acetophenone / Aryl thioether / Tertiary aliphatic/aromatic amine / Aryl alkyl ketone / Aryl ketone / Para-thiazine / Benzenoid
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, tertiary amine, methyl ketone, aromatic ketone (CHEBI:53770)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Mercier J, Dessaigne S, Menguy A, Manez J: Electro-encephalographic study on the action of the combination meprobamate-aceprometazine on various cerebral systems. Arzneimittelforschung. 1974 Feb;24(2):163-6. [PubMed:4406367]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on August 29, 2007 14:13 / Updated on August 02, 2018 04:39